Adam Maeder
Stock Analyst at Piper Sandler
(4.01)
# 531
Out of 4,413 analysts
91
Total ratings
50%
Success rate
11.92%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SILK Silk Road Medical | Maintains: Neutral | $18 → $20 | $17.69 | +13.06% | 6 | May 1, 2024 | |
| NARI Inari Medical | Maintains: Neutral | $55 → $50 | $43.77 | +14.23% | 4 | May 1, 2024 | |
| EW Edwards Lifesciences | Maintains: Neutral | $85 → $88 | $84.70 | +3.90% | 10 | Apr 26, 2024 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $425 → $435 | $371.35 | +17.14% | 11 | Apr 19, 2024 | |
| SWAV ShockWave Medical | Maintains: Overweight | $290 → $360 | $330.60 | +8.89% | 8 | Apr 2, 2024 | |
| STIM Neuronetics | Reiterates: Overweight | $7 → $8 | $3.49 | +129.23% | 1 | Mar 6, 2024 | |
| NYXH Nyxoah | Maintains: Overweight | $15 → $20 | $10.41 | +92.12% | 8 | Mar 6, 2024 | |
| RBOT Vicarious Surgical | Maintains: Neutral | $1.5 → $1 | $0.28 | +256.38% | 4 | Mar 5, 2024 | |
| M Macy's | Downgrades: Market Perform | $23 → $20 | $18.36 | +8.96% | 1 | Feb 29, 2024 | |
| AXNX Axonics | Downgrades: Neutral | $75 → $71 | $66.53 | +6.72% | 6 | Jan 12, 2024 | |
| NVRO Nevro | Maintains: Underweight | $24 → $15 | $10.56 | +42.05% | 11 | Nov 2, 2023 | |
| NSPR InspireMD | Maintains: Overweight | $3.5 → $4.5 | $1.94 | +131.96% | 2 | Nov 2, 2023 | |
| TCMD Tactile Systems Technology | Maintains: Overweight | $25 → $30 | $13.83 | +116.92% | 2 | May 9, 2023 | |
| STXS Stereotaxis | Maintains: Overweight | $6 → $5 | $2.36 | +112.31% | 2 | Mar 6, 2023 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $300 → $305 | $242.03 | +26.02% | 10 | Feb 8, 2023 | |
| ZYXI Zynex | Upgrades: Overweight | $10 → $18 | $11.28 | +59.57% | 2 | Jan 6, 2023 | |
| LIVN LivaNova | Maintains: Overweight | $104 → $99 | $59.40 | +66.68% | 3 | May 5, 2022 |
Silk Road Medical
May 1, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $17.69
Upside: +13.06%
Inari Medical
May 1, 2024
Maintains: Neutral
Price Target: $55 → $50
Current: $43.77
Upside: +14.23%
Edwards Lifesciences
Apr 26, 2024
Maintains: Neutral
Price Target: $85 → $88
Current: $84.70
Upside: +3.90%
Intuitive Surgical
Apr 19, 2024
Maintains: Overweight
Price Target: $425 → $435
Current: $371.35
Upside: +17.14%
ShockWave Medical
Apr 2, 2024
Maintains: Overweight
Price Target: $290 → $360
Current: $330.60
Upside: +8.89%
Neuronetics
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $3.49
Upside: +129.23%
Nyxoah
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $10.41
Upside: +92.12%
Vicarious Surgical
Mar 5, 2024
Maintains: Neutral
Price Target: $1.5 → $1
Current: $0.28
Upside: +256.38%
Macy's
Feb 29, 2024
Downgrades: Market Perform
Price Target: $23 → $20
Current: $18.36
Upside: +8.96%
Axonics
Jan 12, 2024
Downgrades: Neutral
Price Target: $75 → $71
Current: $66.53
Upside: +6.72%
Nevro
Nov 2, 2023
Maintains: Underweight
Price Target: $24 → $15
Current: $10.56
Upside: +42.05%
InspireMD
Nov 2, 2023
Maintains: Overweight
Price Target: $3.5 → $4.5
Current: $1.94
Upside: +131.96%
Tactile Systems Technology
May 9, 2023
Maintains: Overweight
Price Target: $25 → $30
Current: $13.83
Upside: +116.92%
Stereotaxis
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.36
Upside: +112.31%
Inspire Medical Systems
Feb 8, 2023
Maintains: Overweight
Price Target: $300 → $305
Current: $242.03
Upside: +26.02%
Zynex
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $11.28
Upside: +59.57%
LivaNova
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $59.40
Upside: +66.68%